← 返回

工程化巨噬细胞的受控焦亡通过释放溶瘤细菌和炎症信号实现双相抗肿瘤

英文原题:Controlled pyroptosis of engineered macrophages enables biphasic antitumor via the release of oncolytic bacteria and inflammatory signals.

查看英文原题

Controlled pyroptosis of engineered macrophages enables biphasic antitumor via the release of oncolytic bacteria and inflammatory signals.

PubMed 2026/01/29(内容时间) Cell Rep Q1 · IF 7.7(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

基于工程化巨噬细胞的疗法在癌症治疗中具有广阔前景,但受限于药物释放缓慢且不可控,以及巨噬细胞重编程为促肿瘤表型的风险。在此,我们开发了一种热诱导巨噬细胞自溶释放系统——巨噬细胞-微生物封装炸弹(MME-Bomb),该系统将负载吲哚菁绿封装纳米颗粒的工程化巨噬细胞与抗肿瘤减毒鼠伤寒沙门氏菌株相结合。利用光热疗法诱导肿瘤微环境中被封装的巨噬细胞发生可控细胞焦亡和破裂,释放胞内细菌以激发持久的抗肿瘤免疫。通过整合光响应生物调控,我们的方法能够实现工程化细胞的位点特异性激活,增强治疗药物的快速递送,并最大化基于巨噬细胞疗法与细菌疗法之间的协同作用。在临床前癌症模型中,MME-Bomb单独使用以及与检查点抑制剂联合使用均显著降低了肿瘤负荷并改善了生存结局。这一创新策略为推进癌症免疫治疗提供了一个多功能且精准的框架。

展开英文摘要原文

Engineered macrophage-based therapies offer promising potential for cancer treatment but are limited by slow, uncontrolled drug release and the risk of macrophage reprogramming into tumor-promoting phenotypes.

Here, we developed a thermally induced macrophage autolysis release system, the macrophage-microbe encapsulation bomb (MME-Bomb), which combines engineered macrophages loaded with indocyanine green-encapsulated nanoparticles and an antitumor attenuated Salmonella typhimurium strain. Photothermal therapy is used to induce controlled pyroptosis and rupture of the encapsulated macrophages within the tumor microenvironment, releasing intracellular bacteria to stimulate prolonged antitumor immunity.

By integrating light-responsive biomodulation, our approach enables site-specific activation of engineered cells, enhancing the rapid delivery of therapeutic agents and maximizing the synergy between macrophage-based and bacterial therapies. In preclinical cancer models, the MME-Bomb significantly reduced the tumor burden and improved survival outcomes, both alone and in combination with checkpoint inhibitors. This innovative strategy offers a versatile and precise framework for advancing cancer immunotherapies.

论文信息

作者
Wu L、Li C、Qiao L、Li L、Zhang S、Wang B、Sun Y、Qiu J
第一作者单位
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu 210023, P.R. China; Nanjing Generecom Biotechnology Co., Ltd., Nanjing, Jiangsu 210023, P.R. China; Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories, Inc., Changzhou, Jiangsu 213164, P.R. China. Electronic address: lywu@nju.edu.cn.China
通讯作者单位
State Key Laboratory of Pharmaceutical Biotechnology, School of Life Sciences, Nanjing University, Nanjing, Jiangsu 210023, P.R. China; Nanjing Generecom Biotechnology Co., Ltd., Nanjing, Jiangsu 210023, P.R. China; Changzhou High-Tech Research Institute of Nanjing University and Jiangsu TargetPharma Laboratories, Inc., Changzhou, Jiangsu 213164, P.R. China; Faculty of Pharmaceutical Sciences, Xinxiang Medical University, Xinxiang, Henan 453002, P.R. China; School of Biopharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, P.R. China. Electronic address: zchua@nju.edu.cn.China
期刊
Cell reports2026 Feb 24
原文标识
PubMed 41615797 · DOI 10.1016/j.celrep.2025.116918